New Data in Pediatric Patients with Axillary Hyperhidrosis Presented During Late-Breaking Research Forum at the 76th Annual Meeting of the American Academy of Dermatology

New Data in Pediatric Patients with Axillary Hyperhidrosis Presented During Late-Breaking Research Forum at the 76th Annual Meeting of the American Academy of Dermatology Press Release from GlobeNewsWire has been published today, Karol Rutkowski, .

SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) — Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today presented new findings from its glycopyrronium tosylate (formerly DRM04) Phase 3 clinical program. The data showed that when applied topically, the investigational therapy improved disease severity, reduced sweat production and was associated with improved quality of life outcomes for pediatric patients (ages 9 to 16) with primary axillary hyperhidrosis (excessive underarm sweating), compared to vehicle-treated patients.
These findings are consistent with results previously reported in adult patients (ages 17 and older). The data were featured in an oral presentation during the Late-Breaking Research Forums at the 76th Annual Meeting of the American Academy of Dermatology (AAD) in San Diego.Primary axillary hyperhidrosis is a medical condition that results in sweating beyond what is needed for normal body temperature regulation. Glycopyrronium tosylate is an investigational agent formulated as a topical, once-daily anticholinergic wipe, designed to block sweat production by inhibiting the interaction between acetylcholine and the cholinergic receptors responsible for sweat gland activation.“Primary axillary hyperhidrosis has long been associated with social stigma, isolation and embarrassment,” said Adelaide Hebert, M.D., Chief of Pediatric Dermatology at McGovern Medical School at UTHealth, Houston and Children’s Memorial Hermann Hospital, and a lead investigator for the Phase 3 clinical program. “We know that young people with axillary hyperhidrosis are experiencing these effects at a critical time in their physical and social development. If left unaddressed, these effects could lead to profound emotional and social distress that has a negative impact on overall quality of life.1Phase 3 ATMOS-1 and ATMOS-2 Pediatric Post-Hoc AnalysisATMOS-1 and ATMOS-2 were designed as multi-center, randomized, double-blind, vehicle-controlled, four-week Phase 3 trials assessing the efficacy and safety of glycopyrronium tosylate in patients ages 9 years of age and older. Patients had primary axillary hyperhidrosis for six months or more, produced at least 50 mg of sweat in each underarm over a five-minute period and rated the severity of their sweating as a four or higher on an 11-point numerical rating scale (Axillary Sweating Daily Diary (ASDD)/Children’s ASDD [ASDD-C]; Item 2), and had a three or a four on the four-grade Hyperhidrosis Disease Severity Scale (HDSS). All patients were evaluated after four weeks of treatment with glycopyrronium tosylate or vehicle.
 
Overall, 463 patients were randomized to glycopyrronium tosylate and 234 to vehicle. Of these, 44 were pediatric patients, ages 9 to 16 years of age (glycopyrronium tosylate, n=25; vehicle, n=19). Baseline disease characteristics were similar between age groups.
 
Efficacy results were consistent among pediatric and adult patients. Specifically, pooled ASDD/ASDD-C severity scale responder rates for pediatric vs. adult patients were 59.9% vs. 60.2% for glycopyrronium tosylate-treated and 13.0% vs. 28.8% for vehicle-treated patients, respectively.
 
The median absolute changes in sweat production at week four for pediatric vs. adult patients were -64.2 mg vs. -80.6 mg for glycopyrronium tosylate-treated and -53.7 mg vs. -62.0 mg for vehicle-treated patients, respectively.
 
The proportions of patients experiencing a reduction of at least 50 percent in sweat production at week four for pediatric vs. adult patients were 79.9% vs. 74.3% of glycopyrronium tosylate-treated and 54.8% vs. 53.0% of vehicle-treated patients, respectively.
 
The mean decrease from baseline in the Children’s Dermatology Quality of Life Index was -8.1 for glycopyrronium tosylate-treated vs. -1.9 for vehicle-treated patients. This is consistent with that observed for the Dermatology Life Quality Index measure observed for adults, -8.4 for glycopyrronium tosylate-treated vs. -4.7 for vehicle-treated patients.
 
The rates of treatment emergent adverse events* reported for pediatric vs. adult patients were 44.0% vs. 56.7% of glycopyrronium tosylate-treated and 10.5% vs. 34.3% of vehicle-treated patients, respectively. Most were related to anticholinergic activity and were mild, transient and infrequently led to drug discontinuation.“We are encouraged by the new pediatric data analyses from the Phase 3 clinical trials which reported the safety and efficacy of glycopyrronium tosylate in patients as young as nine years old,” said Eugene A. Bauer, M.D., chief medical officer of Dermira and a dermatologist. “Importantly, glycopyrronium tosylate also demonstrated its potential to reduce the daily burden of the condition for individuals at a critical stage in their emotional and social development. These results add to growing body of evidence which suggests that glycopyrronium tosylate could one day be an important new treatment option for millions of axillary hyperhidrosis suffers seeking treatments to more effectively manage this condition.” About Hyperhidrosis
Hyperhidrosis is a condition of sweating beyond what is physiologically required for normal thermal regulation and affects an estimated 4.8% of the U.S. population, or approximately 15 million people.2 Of these, 65 percent, or nearly 10 million people, suffer from sweating localized to the underarms (axillary hyperhidrosis). Studies have further demonstrated that excessive sweating often impedes normal daily activities and can also result in occupational, emotional, social and physical impairment.3,4 New research indicates that one third of survey respondents indicated their primary axillary hyperhidrosis began before the age of 12, suggesting that axillary hyperhidrosis may affect patients younger than previously identified.5
About Glycopyrronium Tosylate and the Phase 3 Studies
Glycopyrronium tosylate is an investigational agent formulated as a topical, once-daily anticholinergic wipe, designed to block sweat production by inhibiting the interaction between acetylcholine and the cholinergic receptors responsible for sweat gland activation.
In November 2017, the U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) for glycopyrronium tosylate based on results from ATMOS-1 and ATMOS-2, Phase 3 clinical trials designed to assess the safety and efficacy of glycopyrronium tosylate compared to vehicle in adolescent and adult patients (ages nine and older) with primary axillary hyperhidrosis. In addition to these two trials, an open-label trial, ARIDO, assessed the long-term safety of glycopyrronium tosylate. The Prescription Drug User Fee Act target date for the completion of the FDA’s review of the NDA is June 30, 2018.About Dermira
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s pipeline includes three late-stage product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate (formerly DRM04), for which a New Drug Application is under review by the U.S. Food and Drug Administration for the treatment of primary axillary hyperhidrosis (underarm sweating beyond what is needed for normal body temperature regulation); olumacostat glasaretil (formerly DRM01), in Phase 3 development for the treatment of acne vulgaris; and lebrikizumab, in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. Dermira is headquartered in Menlo Park, Calif. For more information, please visit http://www.dermira.com. Follow Dermira on Twitter and LinkedIn.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com), LinkedIn page (https://www.linkedin.com/company/dermira-inc) and corporate Twitter account (@DermiraInc) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website, LinkedIn page and Twitter account in addition to following its SEC filings, press releases, public conference calls and webcasts.Forward-Looking Statements
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements with respect to Dermira’s goal of building a leading medical dermatology company dedicated to delivering differentiated, new therapies to the millions of patients living with chronic skin conditions; glycopyrronium tosylate potentially becoming an important new treatment option for millions of axillary hyperhidrosis suffers seeking treatments to more effectively manage the condition; and the target date for completion of the FDA’s review of the NDA for glycopyrronium tosylate. These statements deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to the design, implementation and outcomes of Dermira’s clinical trials; the outcome of future discussions with regulatory authorities; Dermira’s dependence on third-party clinical research organizations, manufacturers and suppliers; and Dermira’s ability to continue to stay in compliance with applicable laws and regulations. You should refer to the section entitled “Risk Factors” set forth in Dermira’s Annual Report on Form 10-K, Dermira’s Quarterly Reports on Form 10-Q and other filings Dermira makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Dermira’s forward-looking statements. Furthermore, such forward-looking statements speak only as of the date of this press release. Dermira undertakes no obligation to publicly update any forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.
*Treatment emergent adverse events are defined as any safety related side effect not present prior to the start of a treatment or any event that already exists in a person that worsens in either intensity or frequency following exposure to the treatment.ReferencesBohaty et. Al., Special Considerations for Children with Hyperhidrosis. Dermatologic Clinics 32 (4): 477-484, 2014.Doolittle et. al., Hyperhidrosis: An Update on Prevalence and Severity in the United States. Arch Dermatol Res. 308:743-749, 2016.Bahar et. al., The prevalence of anxiety and depression in patients with or without hyperhidrosis (HH). J Am Acad Dermatol. 75(6): 1126-1133, 2016.Augustin et. al., Prevalence and disease burden of hyperhidrosis in the adult population. Dermatology. 227: 10-13, 2013.Glaser et. al., Prevalence of Multifocal Primary Hyperhidrosis and Symptom Severity Over Time: Results of a Targeted Survey. Dermatologic Surgery. 42(12), 1347–1353, 2016.Dermira Contacts:Media:
Erica Jefferson
Vice President, Corporate Communications
650-421-7216
erica.jefferson@dermira.com 
Investors:
Ian Clements, Ph.D.
Vice President, Investor Relations
650-422-7753
investor@dermira.com 
Robert H. Uhl
Westwicke Partners
Managing Director
858-356-5932
Robert.uhl@westwicke.com 

AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting

AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting Press Release from GlobeNewsWire has been published today, Karol Rutkowski, .

SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that updated data from the company’s Phase 2a trial of ANB020, AnaptysBio’s wholly-owned anti-IL-33 antibody program, in adult patients with moderate-to-severe atopic dermatitis was presented today at the American Academy of Dermatology (AAD) Annual Meeting in San Diego. The oral presentation, titled “Proof-of-Concept Phase-2a Clinical Trial of ANB020 (Anti-IL-33 Antibody) in the Treatment of Moderate-to-Severe Adult Atopic Dermatitis” was presented by the principal investigator of the ANB020 Phase 2a clinical trial, Dr. Graham Ogg, professor of dermatology at Oxford University in Oxford, England, and is available through the publications section of the AnaptysBio website.
This Phase 2a proof-of-concept trial assessed ANB020 efficacy and safety in 12 moderate-to-severe adult atopic dermatitis patients. The primary efficacy objective of this study was to determine the percentage of patients achieving 50 percent improvement in their Eczema Area Severity Index (EASI) score relative to enrollment baseline (EASI-50) on day 29 post-ANB020 administration.  Each patient was dosed with placebo 14 days following enrollment, and subsequently administered a single 300mg intravenous dose of ANB020 one week after placebo. Key observations presented by Dr. Ogg during the aforementioned presentation included:ANB020 was efficacious in all 12 patients enrolled in this trial with each patient achieving at least EASI-50 on or before day 57 post-ANB020 administration. Rapid clinical response was observed by day 15 post-ANB020 administration with nine of 12 patients (75 percent) achieving EASI-50, of which three patients (25 percent) also achieved EASI score improvement of 75 percent relative to baseline (EASI-75).Day 29 results exceeded the primary efficacy objective of the trial with 10 of 12 patients (83 percent) achieving EASI-50, of which four patients (33 percent) also achieved EASI-75.Efficacy was sustained through day 140 following single dose administration of ANB020 with five of 12 patients (42 percent) achieving EASI-50, of which three patients (25%) also achieved EASI-75.ANB020 efficacy was not limited by disease severity as ANB020 was similarly efficacious in the seven of 12 enrolled patients treated with systemic immuno-modulators pre-study, which exhibited an average EASI baseline score of 36 upon enrollment, relative to the remaining five of 12 enrolled patients that did not require systemic immuno-modulators pre-study and exhibited an average EASI baseline score of 27. The average baseline EASI score upon enrollment across all 12 patients was 32.Other atopic dermatitis efficacy endpoints, including the 5-point Investigator’s Global Assessment (IGA) scale, the SCORing Atopic Dermatitis (SCORAD) scale, Dermatology Life Quality Index (DLQI) and the 5-dimensional pruritus scale, demonstrated rapid and sustained single dose ANB020 efficacy results in a similar manner to the aforementioned EASI results. ANB020 was generally well-tolerated by all patients and no drug-related safety signals were observed.  The most frequent adverse events reported were dizziness in 17% of patients post-placebo and headache in 25% of patients post-ANB020 administration.  A single serious adverse event of depression was reported on Day 140 post-ANB020 administration, which was consistent with the patient’s pre-trial history of depression and was deemed not drug-related. During the first half of 2018, AnaptysBio plans to initiate a Phase 2b randomized, double-blinded, placebo-controlled clinical trial in 200-300 adult patients with moderate-to-severe atopic dermatitis to evaluate various dose levels and dosing frequencies of subcutaneously-administered ANB020, with data expected in 2019.  About ANB020ANB020 is an antibody that potently binds and inhibits the activity of interleukin-33, or IL-33, a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases, including atopic dermatitis, food allergies and asthma. In addition to the aforementioned Phase 2a and Phase 2b clinical trials in moderate-to-severe adult atopic dermatitis patients, AnaptysBio has completed enrollment of a 20-patient randomized, double blinded, placebo-controlled Phase 2a trial in severe adult peanut allergy patients where top-line data are anticipated in March 2018 and is currently enrolling a 24-patient randomized, double blinded, placebo-controlled Phase 2a trial in severe adult eosinophilic asthma patients where top-line data are anticipated in the second quarter 2018.About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The company’s proprietary anti-inflammatory pipeline includes its anti-IL-33 antibody (ANB020) for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma; its anti-IL-36R antibody (ANB019) for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated, which have demonstrated efficacy in an animal model of graft-versus-host disease. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation (SHM) platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology partnership with TESARO and an inflammation partnership with Celgene, including an anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist antibody (TSR-022) and an anti-LAG-3 antagonist antibody (TSR-033), which are currently under clinical development with TESARO, and an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in the clinic with Celgene.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from our clinical trials, including ANB020’s Phase 2a trials in severe adult peanut allergy patients and severe adult eosinophilic asthma patients, and Phase 2b clinical trial in moderate-to-severe adult atopic dermatitis patients; our ability to launch a Phase 2b clinical trial of ANB020 in moderate-to-severe adult atopic dermatitis patients; and the success of our partnership with TESARO and Celgene. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Contact:
Monique Allaire
THRUST Investor Relations
617.895.9511
monique@thrustir.com
Chelcie Lister
THRUST Investor Relations
910.777.3049
Chelcie@thrustir.com

RIOT BLOCKCHAIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Riot Blockchain, Inc. – (RIOT)

RIOT BLOCKCHAIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Riot Blockchain, Inc. - (RIOT) Press Release from GlobeNewsWire has been published today, Karol Rutkowski, .

NEW ORLEANS, Feb. 17, 2018 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 18, 2018 to file lead plaintiff applications in a securities class action lawsuit against Riot Blockchain, Inc. (Nasdaq:RIOT), if they purchased the Company’s securities between November 13, 2017 and February 15, 2018, inclusive (the “Class Period”).  This action is pending in the United States District Court for the District of New Jersey.What You May DoIf you purchased securities of Riot and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-riot/  to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 18, 2018.  About the LawsuitRiot and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company’s principle executive offices were located in Florida, not in Colorado, and in the same location as a significant shareholder who previously worked with the Company’s CEO John O’Rouke (ii) the Company did not intend on holding its Annual Meetings scheduled for December 28, 2017 and February 1, 2018;  and (iii) as a result of the foregoing, the Company’s financial statements were materially false and misleading at all relevant times.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.To learn more about KSF, you may visit www.ksfcounsel.com.Contact:Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com

1-877-515-1850
206 Covington St.
Madisonville, LA 70447

Targa Resources Corp. and Targa Resources Partners Announce Form 10-Ks Available

Targa Resources Corp. and Targa Resources Partners Announce Form 10-Ks Available Press Release from GlobeNewsWire has been published today, Karol Rutkowski, .

HOUSTON, Feb. 17, 2018 (GLOBE NEWSWIRE) — Targa Resources Corp. (NYSE:TRGP) (“TRC” or the “Company”) and Targa Resources Partners LP (“Targa Resources Partners” or the “Partnership”) have filed their respective Form 10-Ks with the Securities and Exchange Commission (SEC) for the year ended December 31, 2017. Both the Company and Targa Resources Partners filed their Form 10-Ks on February 16, 2018. The reports may be accessed via the internet at www.sec.gov.The reports are also available via the internet in the Investors section of the Company’s website at www.targaresources.com, or by going directly to http://ir.targaresources.com/trc/sec.cfm. Hard copies of the report may be ordered free of charge by contacting the Company’s investor relations department by email at investorrelations@targaresources.com, or by phone at (713) 584-1133.About Targa Resources Corp.Targa Resources Corp. is a leading provider of midstream services and is one of the largest independent midstream energy companies in North America. Targa owns, operates, acquires, and develops a diversified portfolio of complementary midstream energy assets. The Company is primarily engaged in the business of: gathering, compressing, treating, processing, and selling natural gas; storing, fractionating, treating, transporting, and selling NGLs and NGL products, including services to LPG exporters; gathering, storing, and terminaling crude oil; storing, terminaling, and selling refined petroleum products.For more information, please visit our website at www.targaresources.comContact investor relations by phone at (713) 584-1133.Sanjay Lad
Director – Investor Relations
Jennifer Kneale
Vice President – Finance

Wonder Forge Debuts New Party Games that are the Scene for Tell-All Fun, Sequined Fashions, a New Twist on Bingo & Dreams of Unimaginable Riches

Wonder Forge Debuts New Party Games that are the Scene for Tell-All Fun, Sequined Fashions, a New Twist on Bingo & Dreams of Unimaginable Riches Press Release from GlobeNewsWire has been published today, Karol Rutkowski, .

Seattle, WA, Feb. 17, 2018 (GLOBE NEWSWIRE) — Toy Fair Booth #2107 – Wonder Forge, maker of great board games that bring people together and a division of Ravensburger North America, introduced new party games for 2018 that are sure to light up game night fun for family and friends alike. The lineup includes a party game so fabulous you’ll wish you could wear it, a family game that makes you think “what would I do with a zillion dollars?!,” an explosively exciting 8-sided dice game, and a delightful preschool game featuring classic farm animals.“Board games bring people together – sometimes for friendly competition, other times to work together to solve problems, but almost always to fill our lives with fun,” said Filip Francke, CEO of Ravensburger. “Wonder Forge’s newest line of games celebrate what can happen when friends and family hit the pause button to play together. Our games bring out the curious, competitive, adventurous and imaginative kid in all of us.”Wonder Forge will debut 26 new games this year, including these standouts: YeahNOPE: The party game that’ll have you wondering how well you know your friendsThe sequin-drenched box is almost as irresistible as this tell-all game, where players must guess what happened and how! Have you told off a boss? Made out with someone in a closet? Players work together to build on the story and speculate using situation cards until the moment the truth is revealed with a swipe of the gold sequined box – Yeah or NOPE. You’ll blush, you’ll giggle, you’ll gasp… because you never know the whole truth!Ages 17 & up | 3-8 Players | MSRP $19.99 | Available August 1 exclusively at TargetBig Money: The game of risky rolls & fabulous fortuneEveryone gets crazy rich, but who will end up the richest? With each roll you’ll have a chance to rake in the dough, but be careful, the tables could turn at any moment or the bank could go bust. Roll the dice and buy amazing investments for your empire – a candy factory, a pro soccer team, or a movie studio. You decide what risks to take as you collect companies and become a Zillionaire!Ages 8 & up | 2-5 Players | MSRP $19.99 | Available August 1 exclusively at WalmartYa Blew It!: The rowdy game of riches and risksWarning: shouts of “Fire in the Hole!” might erupt as you engage in this risk-taking social game. Players dig deep in the card deck to mine for diamonds and stake their claim. However, other prospectors may try to steal from you and give you the shaft!  You can play it safe, or push your luck looking for a bigger claim, either way it’s explosive, and you’ll enjoy the fun with every suspenseful roll of the unique 8-sided dynamite dice!Ages 8 & up | 3-6 Players | MSRP $16.99| Available August 1Farm Animals Spin Go Round:  Barnyard bingo with matching colors, patterns & shapesTake a spin with barnyard friends in this exciting twist on bingo that’s fun for everyone in the family whether 3 or 93. Match the color, pattern, shape, or farm animal to mark your board. Every player has their own spinner and controls their destiny. That is, until someone lands on “Spin Go Round,” and then everyone switches spinners! You never know when the game will take a turn!Ages 3 & up | 2-4 Players | MSRP $14.99| Available August 1Wonder Forge’s 2018 games unleash playfulness and offer something for all ages and all stages. Whether you want to test your knowledge, try your luck, show your skills or giggle out-loud, they provide a fun escape and offer a range of experiences to appeal to players 3 and up.About Wonder ForgeWonder Forge is proud to offer quality games with strong storylines that let players escape and enjoy fun moments together whether you need a little friendly competition, want to explore the worlds of favorite characters, learn something new, or fill a room with laughter. The company works with the industry’s most beloved licenses and has been honored with more than 220 prestigious awards for product excellence, including 5 nominations for the Toy Industry’s T.O.T.Y. Toy of the Year Award in the game category. To learn more, visit wonderforge.com facebook.com/WonderForge, @WonderForge and pinterest.com/wonderforge.About Ravensburger North AmericaRavensburger North America (RNA), a division of Ravensburger AG, is a portfolio of award-winning brands with a shared vision to promote playful development at every stage and every age. The RNA family of brands, including Ravensburger, BRIO, Wonder Forge and ThinkFun, offers an expansive line of thoughtfully designed puzzles, games, toys and activities that focus on quality, craftsmanship and encourage individual thoughtful time or shared moments of fun for the entire family.Attachments:A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/6117aed6-9a43-4fa9-915d-607884cd2ce7Lisa Krueger
Zebra Partners for ThinkFun
(201) 892-3381
lisak@zebrapartners.net

Planes, Canoes and Toys-to-go Fuel Imagination with BRIO's New Play Sets and Classic Toys for 2018

Planes, Canoes and Toys-to-go Fuel Imagination with BRIO's New Play Sets and Classic Toys for 2018 Press Release from GlobeNewsWire has been published today, Karol Rutkowski, .

Newton, NH, Feb. 17, 2018 (GLOBE NEWSWIRE) —Newton, NH (February 17, 2018) – Toy Fair Booth #2107 – BRIO®, the Swedish maker of classic, high-quality toys and a member of the Ravensburger North America Family of Brands, today at Toy Fair in New York, debuted several new play sets and toys designed to spark imaginative play and stand the test of time. From experiencing fun camping adventures, to manning the control tower of an airport, to mastering the labyrinth, BRIO continues to deliver the magic of free-form play and encourages young children to explore and create without limitations and away from screens. “For more than 130 years, BRIO toys have helped to create happy childhood memories with high quality products that become treasures for future generations,” said Filip Francke, CEO of Ravensburger North America / BRIO. “In an increasingly digital world, where kids spend so many hours with screen-time, BRIO toys are more relevant than ever, inspiring children to create their own stories with unlimited possibilities that only come with open-ended play.” BRIO is a global leader in premium quality toys for children 0-5 years, and this year, builds on their line of classic playtime favorites with these new additions: BRIO Camping SetAdventure to the great outdoors any time of year with the BRIO Camping Set. So many little details make this new addition to the “My Home Town” set even more fun as children create their own camping escapades – from a car and camping trailer that gently connect, to a canoe that fits neatly on top of the car (and even has room for the dog when you paddle off). The Camping Set will bring years of play into the home.Play Benefits: Develops creativity and imagination, stimulates gross motor skills and exercises fine motor skills– Available: April 16, 2018 for ages 18mo+ / MSRP $34.99BRIO Airport with Control TowerImagine what it’s like to work all the mechanics of an airport and marvel at the special bird’s eye view from the top of the control tower with BRIO’s Airport with Control Tower. This play set is centered around an airport terminal, and includes a working baggage handling system, darling red plane plus pilot and ground crew. From the easy-to-open canopy of the control tower, to the smooth-running plane and baggage elevator, each piece is made with the highest quality materials including European beech wood. BRIO Airport with Control Tower is a perfect addition to your child’s BRIO train setup, offering endless opportunities for play on the ground and in the sky.Play Benefits: Develops creativity and imagination, encourages storytelling Available: April 16, 2018 for kids ages 3+ / MSRP $69.99 Take Along LabyrinthGenerations of children have grown up playing BRIO Labyrinth. Now, there’s a new version of this turntable maze that’s portable and specially designed for younger kids to enjoy. The Take Along Labyrinth is two-sided and completely sealed so that it can go with you anywhere. No lost marbles, just hours of fun. Made of beech wood and PVC-free plastic, this toy has smooth handles, a marble that glides effortlessly through the maze and will entertain kids for hours. Great for the car or at home.Play Benefits: Develops fine motor skills and supports critical reasoning– Available: April 16, 2018 for kids ages 3+ / MSRP $29.99 BRIO believes toys should open a child’s mind and inspire them to explore their vast and uninhabited imagination. Each of the 2018 products add to the wide-ranging collection of over 140 toys and play sets, all focused on open-ended, joy-filled play to fuel creativity and support a child’s early growth and development.About BRIOFor over a century, our driving force has been to spread joy among children around the world. We want to create happy childhood memories where the imagination can flow freely. BRIO is a Swedish toy brand that creates innovative, high quality and well-designed FSC® certified (N002103) wooden toys that give children a safe and fun play experience. The company was founded in 1884 and is represented in over 30 countries. To learn more visit www.BRIO.us. @BRIOPlay  facebook.com/BRIOPlay/ About Ravensburger North AmericaRavensburger North America (RNA), a division of Ravensburger AG, is a portfolio of award-winning brands with a shared vision to promote playful development at every stage and every age. The RNA family of brands, including Ravensburger, BRIO, Wonder Forge and ThinkFun, offers an expansive line of thoughtfully designed puzzles, games, toys and activities that focus on quality, craftsmanship and encourage individual thoughtful time or shared moments of fun for the entire family.Attachments:A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/057fb6bc-59a4-450a-94e2-4a2aca50045aLisa Krueger
Zebra Partners for Ravensburger
(201) 892-3381
lisak@zebrapartners.net

Shadows, Hackers, Lasers and Cats Will Challenge Your Brainpower and Dial up the Fun in the New 2018 Learning Games Lineup from ThinkFun

Shadows, Hackers, Lasers and Cats Will Challenge Your Brainpower and Dial up the Fun in the New 2018 Learning Games Lineup from ThinkFun Press Release from GlobeNewsWire has been published today, Karol Rutkowski, .

New York, NY, Feb. 17, 2018 (GLOBE NEWSWIRE) —Alexandria, VA, Feb. 17, 2018 – Toy Fair Booth #1919 – ThinkFun®, the award-winning world leader in addictively fun brain games that ignite young minds, today unveiled its 2018 game lineup. Designed to teach critical thinking skills and spark the imagination through fun, hands-on gameplay, the ThinkFun catalog will include a strategy game played in the dark, a coding game focused on cybersecurity, and logic games with real lasers and mischievous cats:Shadows in the Forest: “Play in the Dark” Strategy GameHunker down in a backyard tent or under a fort of blankets because when the lights go out, the fun begins! Shadowlings –  scattered across the forest, hiding in the shadows – must all work together to meet under the same tree to defeat the light. One player is the lantern and tries to freeze the “Shadowlings” or other players by casting the light among a forest of trees to reveal their whereabouts. As the light moves, so do the shadows – allowing the Shadowlings to hide among the trees. If the light freezes all the Shadowlings, it wins. If all the Shadowlings make it to the same tree, they win.– Learning benefits: Strategy, co-operative play and light physics principles.  – Available: May 21, for 2-7 players, ages 8+ with a $24.99 MSRP. Hacker: Cybersecurity Logic GameThis full-strength coding game aims to inspire tweens and teens to pursue a career in cybersecurity. In Hacker, the player takes on the roles of a programmer, hacker and security engineer! As kids work through three phases, each with 40-levels of challenges, they gain a “security mindset,” a vital skill for designing, building, and testing reliable computer systems.– Learning benefits: Coding, problem solving, creative thinking, visual perception, reasoning– Available: July 25, for single players or as a co-operative game, ages 10+ with a $24.99 MSRP.Cat Crimes: Who’s to Blame Logic GameA “ThinkFun-ized” whodunnit game with humor, rich illustrations and fun theme because let’s face it, cats are cool! Tangled yarn and a missing bird… which of the six furry friends was responsible for each Cat Crime? With a little problem solving you’ll be able to use paw prints, toy placement and other clues to figure out exactly where each Cat was sitting at the time of the crime. Starts out easy and then, levels up to expert to challenge even the dog-loving dad at home.– Learning benefits: Logical deduction, reasoning, visualization – Available: Now, for single or collaborative play for ages 8+with a $12.99 MSRP. Laser Chess: The Beam Directing Strategy GameKids love lasers and we’d love to see more of them playing chess, so we put the two together. Laser Chess is a two-player laser chess-like strategy game where you must eliminate your opponents’ players by hitting their target before they hit yours. When your laser hits their target, YOU WIN!  Designed by the inventor of top-selling games Laser Maze® and Khet!– Learning benefits: Strategy, advanced reasoning skills, light and reflection physics– Available: Now, for two players, ages 8+ with a $39.99 MSRP. Now part of 134-year old toy company Ravensburger, after a 2017 acquisition, ThinkFun’s 2018 product line continues to reflect the company’s deep-rooted belief that learning crucial, timeless skills such as logical reasoning and critical thinking can be fun. The games also fit within Ravensburger’s focus on providing high quality products that promote family togetherness and playful development. “Learning drives everything we do – and every game, brainteaser and puzzle we create at ThinkFun,” says ThinkFun Co-founder and Chief Creative Officer Bill Ritchie, “However it’s the infusion of fun that helps spark new thinking, imagination and creativity in young minds. Kids are always up for the challenge and we love seeing them explore unimaginable solutions and new possibilities.” ThinkFun is also celebrating the induction of its Co-Founder and COO, Andrea Barthello, into the Toy Industry Hall of Fame. Launched in 1985, ThinkFun has since grown to become a market leader in STEM games and puzzles in the U.S. and around the world. Barthello has been an active member of the Toy Industry Association (TIA) for many years, serving three terms on the TIA Board, as well as on numerous committees. About ThinkFun Inc.For over 30 years, ThinkFun Inc. has been dedicated to creating games that spark curiosity, cultivate confidence, and nurture life-long learners. Its games encourage interest in Science, Technology, Engineering, and Math (STEM), while generating excitement for a world of learning through play. Innovation, creativity, value, and fun are the four elements that comprise the development of every game. ThinkFun believes that when you ignite the mind, you change the world —and no better way to do so than through play. For more information, visit ThinkFun.com,  @ThinkFun, or facebook.com/ThinkFunGames About Ravensburger North AmericaRavensburger North America (RNA), a division of Ravensburger AG, is a portfolio of award-winning brands with a shared vision to promote playful development at every stage and every age. The RNA family of brands, including Ravensburger, BRIO, Wonder Forge and ThinkFun, offers an expansive line of thoughtfully designed puzzles, games, toys and activities that focus on quality, craftsmanship and encourage individual thoughtful time or shared moments of fun for the entire family.Attachments:A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/39fb3a53-0bcb-4a9d-9530-3827348d8a09Lisa Krueger
Zebra Partners for ThinkFun
2018923381
lisak@zebrapartners.net

SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment Intel Corporation of Class Action Suit and Upcoming Deadline – INTC

SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment Intel Corporation of Class Action Suit and Upcoming Deadline – INTC Press Release from GlobeNewsWire has been published today, Karol Rutkowski, .

NEW YORK, Feb. 17, 2018 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Intel Corporation (“Intel” or the “Company”) (NASDAQ:INTC) and certain of its officers.   The class action, filed in United States District Court, for the Northern District of California, and docketed under 18-cv-00507, is on behalf of a class consisting of investors who purchased or otherwise acquired Intel securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
If you are a shareholder who purchased Intel securities between July 27, 2017, and January 4, 2018, both dates inclusive, you have until March 12, 2018, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.[Click here to join this class action]Intel Corporation designs, manufactures, and sells computer components and related products. The Company’s major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) a fundamental security flaw in Intel’s processor chips renders them susceptible to hacking; (ii) software updates to fix the problems in Intel’s processor chips could cause Intel chips to operate 5-30 percent more slowly; and (iii) as a result, Intel’s public statements were materially false and misleading at all relevant times.On January 2, 2018, post-market, news outlets reported that a significant design flaw in Intel’s processor chips could allow malicious software to read protected areas of a device’s kernel memory—i.e., memory dedicated to the most essential core components of an operating system and their interactions with system hardware—potentially exposing protected information, such as passwords.  The online publication The Register reported that the operating system updates necessary to address the vulnerability would likely result in “a ballpark figure of five to 30 percent slow down, depending on the task and the processor model,” for Intel-based computing devices.On January 3, 2018, media outlets further reported that Google Project Zero’s security team had discovered serious security flaws affecting computer processors built by Intel and other chipmakers. In a blog post, the Project Zero team stated that security flaws—dubbed “Meltdown” and “Spectre”—allow third parties to gather passwords and other sensitive data from a system’s memory.On that same day, Intel published an article on its website entitled “Intel Responds to Security Research Findings,” confirming that its chips contain a feature that makes them vulnerable to hacking.Following these disclosures, Intel’s share price fell $1.59, or over 3.5%, to close at $45.26 per share on January 3, 2018.On January 4, 2018, several news outlets reported that Intel’s CEO, Defendant Krzanich, sold off $24 million worth of Intel stock and options in late November after Intel was informed of vulnerabilities in its semiconductors, but before it was publicly disclosed. Defendant Krzanich sold roughly half his stock and options months after he learned about critical flaws in billions of Intel’s microchips, but before it was publicly disclosed, and now holds only the minimum number of shares he is required to own.Following this news, Intel’s share price fell $0.83, or 1.83%, to close at $44.43 per share on January 4, 2018, damaging investors.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.comCONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888.476.6529 Ext. 9980

Tax Relief Associates a Nationwide Tax Relief Firm that has experience with IRS Tax Settlements

Tax Relief Associates a Nationwide Tax Relief Firm that has experience with IRS Tax Settlements Press Release from GlobeNewsWire has been published today, Karol Rutkowski, .

SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) — If you have not paid back taxes, then you have likely received notifications from the IRS. When you owe the IRS, it is never a good thing. That is why it is important to begin exploring your IRS tax relief. This allows you to take control of your tax situation by obtaining the help necessary to negotiate a proper tax settlement agreement or I/A, where we here at Tax Relief Associates, LLC, can focus on paying down the principal and not just penalties and interest.
It is likely that you have made an honest mistake with the way you filed your taxes or you may have accumulated tax debt unexpectedly. It is imperative to be proactive by reaching out to the IRS before they get to you. Tax Relief Associates can help you fix the problem so that you don’t incur penalties and interest.Whatever your tax “need,” is, here at Tax Relief Associates, LLC, we will strive to help you settle IRS debt. This will allow you to get the most advantageous position and resolution possible in order to avoid being delinquent on payments – which can result in even more penalties and interest.Paying taxes is not always easy. The IRS does accept credit card payments, but you may not want to suffer paying the interest that is associated with this payment method.The IRS tax settlements are based upon how much you owe. When you owe less than $25,000, there are some different options that you can explore. In many instances, you can even form an agreement with the IRS where you lower your tax debts to less than what you owe – and this is always the route you want to take when it is available.You don’t want to deal with the IRS alone because of the constantly changing tax laws and codes. Also by having professionals represent you, such as the Enrolled Agents here at Tax Relief Associates, LLC, licensed by the US Department of Treasury, who will get REAL results for you. Tax relief is possible with Tax Relief Associates, LLC where professional EAs (Enrolled Agents), Tax Attorneys, CPA’s Accountants, and Tax Preparers are on your side every step of the way.The IRS can be extremely difficult to deal with and that is why it can be advantageous to work with a professional company and tax firm that has experience with IRS tax settlements and negotiations as well as dealing with IRS Revenue Officers along with State Tax Officers.Tax Relief Associates, a nationwide Tax Relief firm, protect yourself from the IRS; Tax Relief Associates can help protect you from taxes incurred in a previous marriage. Call Tax Relief Associates now and talk to one of our specially trained tax repair specialists to get started on your case. Let Tax Relief Associates get you back on the road to freedom from IRS tax debt.Author: Joshua Van Horn
Organization: Tax Relief Associates, LLC
Address: 4231 Balboa Ave, San Diego, CA 92117
Phone: 1-833-827-2728
https://irstaxreliefassociates.com/A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7282c8be-6615-4501-a585-dc7117f2730f

Tax Relief Associates Explains The IRS Innocent Spouse Relief Program

Tax Relief Associates Explains The IRS Innocent Spouse Relief Program Press Release from GlobeNewsWire has been published today, Karol Rutkowski, .

SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) — Mr. Van Horn of Tax Relief Associates provides an insight into the IRS Innocent Spouse Relief Program.
When couples file a joint tax return, each individual is liable for an equal payment of all taxes including penalties and interest for that given year. In the case of divorce or a divorce decree stating that one individual is responsible for the tax debt, the IRS can legally go after just one or even both parties for the entire amount of the tax debt. The IRS recognizes that there are certain situations, such as an understatement of taxes owed, in which it would be unfair to hold both parties liable for the tax debt, so the IRS created the Innocent Spouse Relief.When you get married or if you are married, you can file your income tax jointly. Each individual is liable for an equal payment of all taxes including penalties and interest for that given year.Sometimes though problems arise, for instance, in the case of you or your spouse making mistakes on the tax return resulting in an understatement of taxes owed; or you and your spouse get a divorce. The IRS recognizes these certain situations, in which it would be unreasonable to hold both parties liable for the tax debt.The rules for Innocent Spouse Relief states that:The innocent spouse did not know and would not have had a reason to know that there was an understatement of taxes owed.The understatement of taxes owed was the liability of the other individual.That it would be unfair to hold the innocent spouse responsible for the actions of the other individual.Protect Yourself from the IRS; Tax Relief Associates can help protect you from taxes incurred in a previous marriage. Call Tax Relief Associates now and talk to one of our specially trained tax repair specialists to get started on your case. Let Tax Relief Associates get you back on the road to freedom from IRS tax debt.Author: Joshua Van Horn
Organization: Tax Relief Associates, LLC
Address: 4231 Balboa Ave, San Diego, CA 92117
Phone: 1-833-827-2728
https://irstaxreliefassociates.com/A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/17b57cfa-c3c1-41b8-9607-04d2eb5de007